Skip to main content
Skip to footer

Medical Professionals
Press Releases
Contact

Atara Biotherapeutics

Our Company
- About Us
- Responsibility
Our Focus
Technology
Pipeline
Patients & Families
Investors & Media
Careers
Contact
Medical Professionals
Press Releases
Suppliers
LinkedIn
Twitter

News
Careers

ATA3219: A Potent Next Generation Allogeneic Off the Shelf CD19 CAR T Therapy Without the Need for Gene Editing

Home
Site Map
Terms of Use
Privacy Policy

Medical Professionals
Press Releases
Suppliers

Our Company
Technology
Pipeline
Investors and Media
Patients and Families
Careers
Contact

Our Company
About Us
Responsibility

Technology

Investors and Media
Investors and Media
News and Events
Financial Results
ATRA Stock
Analyst Coverage
SEC Filings
Governance

Pipeline
Atara Pipeline
Tab-cel^®
ATA188
ATA2271/ATA3271
ATA3219

Careers
Careers Home
Career Areas
Job Search

Contact

Patients and Families
Our Mission
Stories of Strength
About EBV
PTLD
Multiple Sclerosis
Clinical Studies
Expanded Access

© 2024 Atara Biotherapeutics, Inc. All rights reserved.